Health ❯ Healthcare ❯ Pharmaceuticals

Cancer Treatment

Breast Cancer Immunotherapy Clinical Trials Bladder Cancer Multiple Myeloma Small Cell Lung Cancer Prostate Cancer Keytruda Drug Development Non-Small Cell Lung Cancer

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

The Denton site extends a $23 billion U.S. buildout designed to place short‑lived therapies closer to patients.

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

Erasca Shares Plunge After Trial Death and Patent Challenge

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

HHS Chief Distances From FDA Replimune Denial as Oncologists Dispute Review

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Dosing Disputes, Counterfeits, and a Patent Wall Put Keytruda Under Fresh Scrutiny

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

Brazil Sets Deal to Produce Cancer Immunotherapy for the Public Health System

EU Drug Panel Backs Imdylltra for Relapsed Small Cell Lung Cancer

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel